– USA, MA – Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the appointment of Geno Germano to the role of Chair of the Board of Directors, succeeding Kevin Starr who is retiring from the Board.
“I am thrilled to have Geno assume the role of Chair of the Board at a time of great momentum for Sage. Geno has decades of experience in bringing life-changing treatments to market and his insight and expertise are very well-suited to help support our commercialization goals and advance a robust pipeline of clinical and early-stage programs,” said CEO, Barry Greene.
About Geno Germano
Geno Germano is the President and CEO at Elucida Oncology and has served on Sage’s board of directors since 2016. He has over 30 years of experience in the pharmaceutical industry and a consistent track record of improving operating performance and increasing shareholder value across numerous leadership roles in multiple therapeutic categories and global markets at Intrexon, Pfizer, Wyeth, and Johnson & Johnson.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to our mission of pioneering solutions to deliver life-changing brain health medicines, so every person can thrive. Sage developed the only two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. Sage was founded in 2010 and is headquartered in Cambridge, Mass. Find out more at www.sagerx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
